Primary vitreoretinal lymphoma: a diagnostic and management challenge

Area of Science:

• Ophthalmology
• Hematology
• Oncology

Background:

• Primary vitreoretinal lymphoma (PVRL) is a rare intraocular lymphoma, a subtype of primary CNS lymphoma (PCNSL).
• PVRL can lead to irreversible vision loss and CNS relapse, a primary cause of mortality.
• The exact pathophysiology of PVRL remains elusive, though it involves tumor cell migration and proliferation in the eye's immune-privileged microenvironment.

Purpose of the Study:

• To summarize current knowledge on PVRL, including its pathophysiology, diagnosis, and treatment.
• To highlight diagnostic challenges and the need for improved diagnostic tools.
• To review therapeutic strategies and identify areas for future research.

Main Methods:

• Literature review of PVRL pathophysiology, diagnosis, and treatment.
• Analysis of diagnostic modalities including cytology, interleukin levels, molecular biology, and imaging.
• Evaluation of treatment outcomes from retrospective and small cohort studies.

Main Results:

• Diagnosis is challenging due to rarity and fragility of cells; requires multidisciplinary approach.
• Intravitreal therapies (methotrexate, rituximab) and radiotherapy clear ocular tumor cells but don't prevent CNS relapse.
• Systemic chemotherapy with high-dose methotrexate may reduce CNS relapse risk; novel agents show promise in relapsed cases.

Conclusions:

• PVRL necessitates urgent multi-institutional prospective studies for treatment validation.
• Refined diagnostic and therapeutic strategies are needed to improve patient outcomes.
• Further research into PVRL pathophysiology and novel systemic treatments is warranted.